Follicle-stimulating Hormone (fsh) Or Derivative Patents (Class 514/9.9)
-
Publication number: 20120046228Abstract: The present invention relates to methods and reagents for modulating ovulation in humans and non-human animals.Type: ApplicationFiled: August 18, 2011Publication date: February 23, 2012Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventor: Carlos A. Molina
-
Publication number: 20120035109Abstract: This invention provides superactive analogs of FSH demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type FSH. In particular, the analogs of the invention demonstrate at least a ten fold increase in potency or at least a ten percent increase in maximal efficacy as compared to wild type protein. The analogs are particularly useful in treating subjects showing low FSH receptor expression or poor FSH receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.Type: ApplicationFiled: July 21, 2011Publication date: February 9, 2012Applicant: Trophogen, Inc.Inventors: Mariusz W. SZKUDLINSKI, Bruce D. Weintraub
-
Publication number: 20120021984Abstract: This invention relates to the field of glycoprotein hormone analogs and their uses as agonists, antagonists, targeting vectors, and immunogens. In particular, this invention describes a method for stabilizing a heterodimer that permits the preparation of functional glycoprotein hormone analogs. The analogs of present invention comprise at least one alpha subunit polypeptide and at least one beta subunit polypeptide, wherein the seatbelt region of the beta subunit is linked to the alpha subunit. The invention also provides for a beta subunit polypeptide wherein the C-terminal amino acid is from residue 10 to residue 20 of the seatbelt region.Type: ApplicationFiled: May 24, 2011Publication date: January 26, 2012Applicant: University of Medicine and Dentistry of New JerseyInventor: William R. Moyle
-
Publication number: 20120021985Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: June 3, 2011Publication date: January 26, 2012Inventors: Craig A. Rosen, William A. Haseltine
-
Publication number: 20120015879Abstract: A novel ovulatory induction paradigm entails administration of hCG in combination with FSH during all stages of treatment, where the ratio of FSH to hCG is adjusted to optimize ovulatory stimulation and minimize complications. The use of compositions characterized by various FSH:hCG ratios enables the practitioner readily to tailor the treatment regimen and accommodate different therapeutic goals as well as individual patient responses to gonadotropin administration.Type: ApplicationFiled: May 31, 2011Publication date: January 19, 2012Inventor: Marco Filicori
-
Publication number: 20120009260Abstract: A therapeutic or bioeffecting film delivery system which includes nanoparticles having actives bound to or associated with the nanoparticles and which when administered allow the active to perform a therapeutic or bioeffecting function.Type: ApplicationFiled: June 10, 2011Publication date: January 12, 2012Inventors: Alexander M. Schobel, Garry L. Myers, Keith Joseph Kendall, Thomas Rademacher, Jan Mous, Justin N. W. Barry, Phillip Williams, Africa Garcia Barrientos
-
Publication number: 20110275567Abstract: A stable aqueous composition containing follicle-stimulating hormone, which comprises follicle-stimulating hormone and histidine as a stabilizing agent.Type: ApplicationFiled: November 2, 2009Publication date: November 10, 2011Applicant: ASKA PHARMACEUTICAL CO., LTD.Inventors: Hajime Asada, Hiroshige Kataoka
-
Publication number: 20110275886Abstract: The present invention provides a method to select a non-human female animal subject having the capacity to produce appropriate number of transferable embryos or fertilizable oocytes in said animal, said method comprising the determination of the anti-Mullerian hormone concentration in a biological sample before an ovarian superovulatory treatment. The present invention is further directed to the use of AMH as a predictive marker of number of transferable embryos or fertilizable oocytes able to be produced in a non-human female animal.Type: ApplicationFiled: December 18, 2009Publication date: November 10, 2011Inventors: Danielle Monniaux-Jaudet, Stéphane Fabre, Rozenn Dalbies-Tran
-
Patent number: 8048849Abstract: A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.Type: GrantFiled: June 2, 2009Date of Patent: November 1, 2011Assignee: Modigene, Inc.Inventors: Fuad Fares, Udi Eyal Fima
-
Patent number: 8048848Abstract: A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an IFN protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.Type: GrantFiled: July 14, 2008Date of Patent: November 1, 2011Assignee: Prolor Biotech Ltd.Inventors: Fuad Fares, Udi Eyal Fima
-
Publication number: 20110239318Abstract: The invention provides methods for producing biofuel from algae, that use fish which have a high capacity of producing and/or accumulating lipids to harvest algae from an algal culture. The invention also provides methods for growing fish that result in a high lipid content. The invention also provides methods for creating fish that have a high capacity of producing and accumulating lipids by breeding and/or recombinant DNA techniques. Also included are transgenic fish that have a higher lipid content than wild-type fish.Type: ApplicationFiled: November 17, 2009Publication date: September 29, 2011Applicant: LiveFuels, Inc.Inventors: David Stephen, Gaye Elizabeth Morgenthaler
-
Publication number: 20110223230Abstract: A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.Type: ApplicationFiled: May 19, 2011Publication date: September 15, 2011Applicant: ASCENDIS PHARMA A/SInventors: Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
-
Publication number: 20110218147Abstract: In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.Type: ApplicationFiled: May 19, 2011Publication date: September 8, 2011Applicant: Acceleron Pharma Inc.Inventors: John Knopf, Jasbir Seehra, Matthew L. Sherman
-
Publication number: 20110201554Abstract: Provided is an aqueous formulation of a human follicle stimulating hormone (hFSH) which is stabilized to maintain the activity of hFSH for a prolonged period of time. The formulation of the present invention is an aqueous formulation comprising a therapeutically effective amount of hFSH stabilized in a phosphate buffer containing glycine, methionine and a non-ionic surfactant, preferably polysorbate 20, which is capable of maintaining the activity of hFSH for an extended period of time.Type: ApplicationFiled: September 25, 2006Publication date: August 18, 2011Applicant: LG LIFE SCIENCES, LTD.Inventors: Suk Young Choi, Hoon Sung Jeh
-
Publication number: 20110195020Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.Type: ApplicationFiled: February 4, 2011Publication date: August 11, 2011Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20110183886Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.Type: ApplicationFiled: March 29, 2011Publication date: July 28, 2011Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
-
Patent number: 7985732Abstract: A novel ovulatory induction paradigm entails administration of hCG in combination with FSH during all stages of treatment, where the ratio of FSH to hCG is adjusted to optimize ovulatory stimulation and minimize complications. The use of compositions characterized by various FSH:hCG ratios enables the practitioner readily to tailor the treatment regimen and accommodate different therapeutic goals as well as individual patient responses to gonadotropin administration.Type: GrantFiled: June 2, 2004Date of Patent: July 26, 2011Assignee: Ferring B.V.Inventor: Marco Filicori
-
Patent number: 7964562Abstract: A novel ovulatory induction paradigm entails administration of hCG in combination with FSH during all stages of treatment, where the ratio of FSH to hCG is adjusted to optimize ovulatory stimulation and minimize complications. The use of compositions characterized by various FSH:hCG ratios enables the practitioner readily to tailor the treatment regimen and accommodate different therapeutic goals as well as individual patient responses to gonadotropin administration.Type: GrantFiled: October 31, 2007Date of Patent: June 21, 2011Assignee: Ferring B.V.Inventor: Marco Filicori
-
Patent number: 7956034Abstract: FSH mutant with increased glycosylation and longer half-life is described. The use of this FSH mutant for inducing folliculogenesis in human patients is also described.Type: GrantFiled: January 16, 2007Date of Patent: June 7, 2011Assignee: Merck Serono SAInventors: Marco Muda, Xuliang Jiang, Sean D. McKenna
-
Publication number: 20110123577Abstract: A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for transdermal delivery of the drug, wherein the composition is stable at room temperature.Type: ApplicationFiled: February 1, 2011Publication date: May 26, 2011Inventors: Nicholas V. Perricone, Chim Potini
-
Publication number: 20110105398Abstract: Preparations including recombinant FSH (rFSH).Type: ApplicationFiled: April 16, 2009Publication date: May 5, 2011Applicant: Ferring International Center SAInventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
-
Publication number: 20110054410Abstract: The present invention relates to a liquid pharmaceutical composition comprising a follicle stimulating hormone polypeptide and benzalkonium chloride and benzyl alcohol as preservatives. The composition further comprises optionally one or more other pharmaceutically acceptable excipients. In one embodiment, the composition contains methionine as an antioxidant. The composition shows a good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where follicle stimulating hormone preparations are considered as useful remedies.Type: ApplicationFiled: February 9, 2009Publication date: March 3, 2011Applicant: BIOGENERIX AGInventors: Sascha Stolzenberger, Erich Kohler
-
Publication number: 20100297066Abstract: Novel biodegradable compositions are disclosed. The biodegradable compositions include at least one hydroxyl-terminated component and at least one bioactive peptide in a linear chain. The compositions may be utilized as medical devices including drug delivery devices, tissue adhesives and/or sealants.Type: ApplicationFiled: May 14, 2008Publication date: November 25, 2010Inventors: Joshua B. Stopek, Brian Cuevas
-
Publication number: 20100279922Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.Type: ApplicationFiled: July 10, 2006Publication date: November 4, 2010Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
-
Publication number: 20100261649Abstract: The invention relates to liquid pharmaceutical formulations of luteinizing hormone (LH) for single- or multi-dose administration.Type: ApplicationFiled: October 29, 2008Publication date: October 14, 2010Inventors: Rita Agostinetto, Fabrizio Samaritani, Alessandra Del Rio, Joel Richard
-
Publication number: 20100255100Abstract: This invention relates to methods for the stabilization, storage and delivery of biologically active macromolecules, such as proteins, peptides and nucleic acids. In particular, this invention relates to protein or nucleic acid crystals, formulations and compositions comprising them. Methods are provided for the crystallization of proteins and nucleic acids and for the preparation of stabilized protein or nucleic acid crystals for use in dry or slurry formulations. The present invention is further directed to encapsulating proteins, glycoproteins, enzymes, antibodies, hormones and peptide crystals or crystal formulations into compositions for biological delivery to humans and animals. According to this invention, protein crystals or crystal formulations are encapsulated within a matrix comprising a polymeric carrier to form a composition.Type: ApplicationFiled: October 30, 2009Publication date: October 7, 2010Applicant: Altus Pharmaceuticals Inc.Inventors: Alexey J. Margolin, Nazar K. Khalaf, Nancy L. St. Clair, Scott L. Rakestraw, Bhami C. Shenoy
-
Publication number: 20100249026Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: May 20, 2010Publication date: September 30, 2010Inventors: CRAIG A. ROSEN, WILLIAM A. HASELTINE